Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-08
2005-02-08
Celsa, Bennett (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S308000, C530S324000
Reexamination Certificate
active
06852690
ABSTRACT:
A composition and method for improved parenteral administration of nutrients is provided. The method comprises co-administration of nutrients, especially carbohydrates, and an insulinotropic peptide, or its derivatives, analogs, and fragments. The method and composition provide high carbohydrate nutrition while avoiding hyper- and hypoglycemia and their attendant deleterious effects.
REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5364838 (1994-11-01), Rubsamen
patent: 5383848 (1995-01-01), Hillman et al.
patent: 5424286 (1995-06-01), Eng
patent: 5487898 (1996-01-01), Lu et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5614492 (1997-03-01), Habener
patent: 5846937 (1998-12-01), Drucker
patent: 5912229 (1999-06-01), Thim et al.
patent: 6006753 (1999-12-01), Efendic
patent: 0 619 322 (1994-10-01), None
patent: 9111457 (1991-08-01), None
patent: WO 9311799 (1993-06-01), None
patent: WO 9318785 (1993-09-01), None
patent: WO 9707814 (1997-03-01), None
patent: 9731943 (1997-09-01), None
patent: 9739031 (1997-10-01), None
patent: 9808531 (1998-03-01), None
patent: 9808873 (1998-03-01), None
patent: 9819698 (1998-05-01), None
patent: 9820895 (1998-05-01), None
patent: 9929336 (1999-06-01), None
patent: 9940788 (1999-08-01), None
Amland, P.F. et al., “Effects of Atropine on GIP-induced Insulin and Pancreatic Polypeptide Release in Man”,Scand J. Gastronenterol, 20:321-324 (1985).
Baer, A.R. et al., “Effects of Gastric Inhibitory Polypeptide in the Response to Prolonged Parenteral or Enteral Alimentation in Rats”,Diabetes, 34(11):1108-1112 (Nov. 1985).
Guo, Jian-Hwa et al., “Bioadhesive Polymer Buccal Patches For Buprenorphine Controlled Delivery: Solubility Consideration”,Drug Development and Industrial Pharmacy, 21(17):2013-2019 (1995).
Gutniak, M. et al., “Potential Therapeutic Levels of Glucagon-Like Peptide 1 Achieved in Humans by a Buccal Tablet”,Diabetes Care, 19(8):843-848 (Aug. 1996).
Leone-Bay, A. et al., “Microsphere Formation in a Series of Derivatized α-Amino Acids: Properties, Molecular Modeling, and Oral Delivery of Salmon Calcitonin”,Journal of Medicinal Chemistry, 38(21):4257-4262 (1995).
Schmidt, W. et al., “Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets”,Diabetologia, 28(9):704-707 (Sep. 1985).
Rabinovitch et al.,I, Endocrinology 94:1139(1974).
Dupre et al., Cndocrinol. Metab. 37:826(1973).
Gutniak et al., New England Journal of Medicine 326:1316.
Nathan et al., Diabetes Care 15:270 (1992).
Nauck et al., Diabetologia 36:741 (1993).
Hargrove et al., Metabolism 44:1231 (1995).
Gutniak et al., Diabetes Care 17:1039 (1994).
Ranganath et al., Gut 38:916 (1996).
Pierluissi et al., Acta Cientificia Venezolana 46(2):89 (1995).
Creutzfeldt et al., Diabetes Care 16:580 (1996).
Shaw et al., Annals of Surgury 209(N1):63 (1989).
Suzuki et al., Endrocrinology 125:3109 (1989).
Rowland et al., Nutrition 12:626 (1996).
Sachs et al., Chirurg 59:24 (1988).
Mizock et al., American Journal of Medicine 98:75 (1995).
Deacon et al., Diabetes 44:1126 (1995).
Navarro et al., J. Neurochemistry 67:1982 (1996).
Turton et al., Nature 379:69 (1996).
Tang-Christensen et al., American Journal of Physiology 271:R848 (1996).
Barragan, J.M. et al., Regul. Peptides 67:63 (Nov. 1996).
Barragan et al., American Journal of Physiology 226 E459 (1994).
O'Shea et al., Neuroreport 7:830 (1996).
Japanese Patent Abstract, JP8268908, Drugs for maintaining the function of gastrointestinal mucosa—contain Gastrointestinal hormone . . . , 10/96, Dialog (R) File 351:Derwent WPI 96-514913/199651.
Japanese Patent Abstract, JP5207846, Fermented milk and lactobacilli beverage easily . . . , 8/93 Dialog (R) File 351:Derwent WPI 93-297440/199338.
Nauck Michael A.
Wagner Fred A.
Amylin Pharmaceuticals Inc.
Arnold & Porter LLP
Celsa Bennett
LandOfFree
Method and composition for enhanced parenteral nutrition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for enhanced parenteral nutrition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for enhanced parenteral nutrition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3512665